September 26, 2018 08:45 AM EDT
R&D

Aldeyra shares soar on pos­i­tive PhII dry eye da­ta — but lose some steam on sec­ond look

John Carroll

Editor & Founder

Shares of Aldeyra Ther­a­peu­tics $ALDX soared in pre-mar­ket trad­ing Wednes­day as the biotech tout­ed pos­i­tive da­ta for its lead drug in treat­ing dry eye dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times